![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Update from Study A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children aged 2-<18 years
|
|
|
Reported by Jules Levin
IAS 2013 June 30-July 3 Kulala Lumpur
M Vourvahis,1 L McFadyen,2 T Checchio,3 C Giaquinto,4 L Keet,5 SR Valluri,1 A Fang,1 G Mukwaya,1 J Heera6
1Pfizer Inc, Specialty Care, New York, NY, USA; 2Pfizer Inc, Primary Care, Sandwich, Kent, UK; 3Pfizer Inc, Primary Care, Groton, CT, USA;
4Department of Pediatrics, University of Padova, Padova, Italy; 5Department Pediatrics, University of the Free State, Bloemfontein, South
Africa; 6Pfizer Inc, Specialty Care, Groton, CT, USA
![IAS1.gif](../images/072413/072413-2/IAS1.gif)
![IAS2.gif](../images/072413/072413-2/IAS2.gif)
![IAS3.gif](../images/072413/072413-2/IAS3.gif)
![IAS4.gif](../images/072413/072413-2/IAS4.gif)
![IAS5.gif](../images/072413/072413-2/IAS5.gif)
![IAS6.gif](../images/072413/072413-2/IAS6.gif)
![IAS7.gif](../images/072413/072413-2/IAS7.gif)
![IAS8.gif](../images/072413/072413-2/IAS8.gif)
![IAS9.gif](../images/072413/072413-2/IAS9.gif)
![IAS10.gif](../images/072413/072413-2/IAS10.gif)
![IAS11.gif](../images/072413/072413-2/IAS11.gif)
![IAS12.gif](../images/072413/072413-2/IAS12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|